mouse liver, mainly through miR-155/GSK-3β-NF-κB signaling pathway. The results in the present study provided evidence that targeting miR-155 might be a potential therapeutic target for liver inflammation. Further animal and clinical studies are required, which may largely strengthen these ...
N. GSK3beta: role in therapeutic landscape and development of modulators. Br. J. Pharmacol. 160, 1–19 (2010). Article CAS PubMed PubMed Central Google Scholar Cohen, P. & Goedert, M. GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug Discov. 3, 479–487 (2004)...
GSK-3beta acts upstream of Fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2 The Journal of Biological Chemistry, 282 (22) (2007), pp. 16502-16510 View PDFView articleCrossrefView in ScopusGoogle Scholar Kallifatidis et al, 2011 G. Kallifatidis, S. ...
Pancreatic cancer is one of the most difficult malignancies to treat owing to the rapid acquisition of resistance to chemotherapy. Gemcitabine, a first-line treatment for pancreatic cancer, prolongs patient survival by several months, and combination treatment with gemcitabine and other anti-cancer drugs...
We sought to evaluate elraglusib (9-ING-41), a small molecule that targets GSK-3, which has the potential to increase the efficacy of ICB. We chose to evaluate elraglusib, which inhibits both alpha and beta isoforms, because it is a clinically-relevant small molecule with superior pharmaco...
The enzyme 11-beta hydroxysteroid dehydrogenase type 1 (HSD11B1) converts inactive cortisone into active cortisol, a process facilitated by hexose-6-phosphate dehydrogenase (H6PD). The production of cortisol through this reaction could elevate intra-abdominal cortisol levels, potentially playing a role...
[14]. Additionally, PLE0 plays a role in regulating epithelial–mesenchymal transition (EMT) by suppressing the expression of type II transforming growth factor beta receptor (TβRII) and the phosphorylation of TβRI in A549 lung cancer cells [15]. Additionally, a polysaccharide fraction (PLE-...